CompuMed (CMPD) Stock Analysis & Winston Score
CompuMed is a small healthcare technology company that helps doctors read and interpret medical tests remotely. Its main service is telemedical diagnostics — it transmits electrocardiogram (ECG) heart tests and other patient data from clinics or hospitals to specialist physicians who review the results and send back reports. The company primarily serves healthcare providers like hospitals, clinics, and physician offices. CompuMed earns revenue by charging fees each time a test is transmitted and interpreted, making it a transaction-based service model. It operates mainly in the United States and is a very small company, with a market cap that rounds to essentially zero at current levels. Its gross margin near 48% shows the service itself is reasonably profitable, but the company is currently losing money at the operating level, which is a meaningful risk for a business this size. The key challenge going forward is scaling its customer base enough to cover fixed costs and reach consistent profitability, especially as larger health systems build similar capabilities in-house.
Winston Score: 27/100 — Below Average
Below-average fundamentals — multiple weak pillars.
- Quality: Weak (6/30)
- Growth: Mixed (6/20)
- Cash Flow: Weak (1/10)
- Stability: Good (5/10)
- Valuation: Data not available (0/10)
- Ownership: Good (8/15)
Key Facts
Price: $5.98
Market Cap: $8M
Sector: Healthcare
Industry: Medical - Healthcare Information Services
Exchange: Other OTC


